Ryvu Therapeutics SA (RVU) - Total Liabilities

Latest as of March 2026: zł159.63 Million PLN ≈ $43.93 Million USD

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł159.63 Million PLN (≈ $43.93 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ryvu Therapeutics SA (RVU) investment intensity to see how much of total assets are deployed in long-term investments.

Ryvu Therapeutics SA - Total Liabilities Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ryvu Therapeutics SA assets under control.

Ryvu Therapeutics SA Competitors by Total Liabilities

The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Star Holdings NASDAQ:STHO	USA	$304.33 Million
Bogota Financial Corp NASDAQ:BSBK	USA	$785.12 Million
TCM Group CO:TCM	Denmark	Dkr764.30 Million
icad inc NASDAQ:ICAD	USA	$8.68 Million
Kalray SA PA:ALKAL	France	€23.73 Million
Lhyfe SA PA:LHYFE	France	€176.05 Million
Forsys Metals Corp. TO:FSY	Canada	CA$358.54K
DAM CAPITAL ADVISORS LTD NSE:DAMCAPITAL	India	Rs1.73 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ryvu Therapeutics SA balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.26	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.86	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	zł153.69 Million ≈ $42.30 Million	-34.57%
2024-12-31	zł234.89 Million ≈ $64.65 Million	+63.56%
2023-12-31	zł143.61 Million ≈ $39.52 Million	+9.14%
2022-12-31	zł131.59 Million ≈ $36.21 Million	+121.55%
2021-12-31	zł59.39 Million ≈ $16.35 Million	-17.42%
2020-12-31	zł71.92 Million ≈ $19.79 Million	+13.92%
2019-12-31	zł63.13 Million ≈ $17.38 Million	+3.77%
2018-12-31	zł60.84 Million ≈ $16.74 Million	+53.72%
2017-12-31	zł39.58 Million ≈ $10.89 Million	+18.46%
2016-12-31	zł33.41 Million ≈ $9.19 Million	+81.95%
2015-12-31	zł18.36 Million ≈ $5.05 Million	+4.63%
2014-12-31	zł17.55 Million ≈ $4.83 Million	+18.19%
2013-12-31	zł14.85 Million ≈ $4.09 Million	+51.28%
2012-12-31	zł9.82 Million ≈ $2.70 Million	+62.45%
2011-12-31	zł6.04 Million ≈ $1.66 Million	-31.08%
2010-12-31	zł8.77 Million ≈ $2.41 Million	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$106.26 Million

zł386.11 Million PLN

Market Cap Rank

#19053 Global

#147 in Poland

Share Price

zł16.70

Change (1 day)

-1.65%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00